Author

Ryan R. Posey

Harvard UniversityORCID 0000-0002-4537-1257Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Molecular Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:differential expression· 1 Research Focus:gene regulatory network inference· 1 Assay:proteomics· 1

Frequent Co-Authors

David Benson ChouiD· 2 shared Jonathan D. LeeiD· 2 shared Aliçan ÖzkaniD· 1 shared Amanda R. JiangiD· 1 shared Amyah C. Harris· 1 shared Anna M. Howley· 1 shared Bogdan BudnikiD· 1 shared Bon Q. TrinhiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

David Benson ChouORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintSep 30, 2026

Tumor suppressor-like mutations mark a dosage-constrained dependency in leukemia

Jonathan D. Lee, Madison M. Uyemura, Francisca Lamini…·Frank John Slack

The paper shows that oncogene-imposed dosage constraints can lead to mutations resembling tumor suppressor loss, which are essential in APL.

DOI 10.64898/2026.09.29.755484

humanbulk RNA-seq

𝕏 PostBluesky

Molecular BiologybioRxivPreprintNov 5, 2025

Endothelial CLK2 as a therapeutic target for acute radiation syndrome

Ryan R. Posey, Aliçan Özkan, Yuncheng Man…·Donald E. Ingber

This study identifies CLK2 as a therapeutic target for acute radiation syndrome by showing CLK2 inhibitors protect endothelial cells and reverse radiation injury in human organ models.

DOI 10.1101/2025.11.05.686891

humanproteomics

𝕏 PostBluesky